Human Organoids Market Report 2026

The human organoids market size has grown rapidly in recent years. It will grow from $1.71 billion in 2025 to $1.99 billion in 2026 at a compound annual growth rate (CAGR) of 16.6%. The growth in the historic period can be attributed to advancements in stem cell research, limitations of traditional 2D cell cultures, rising demand for predictive preclinical models, increased investment in biomedical research, growing focus on reducing animal testing.

The human organoids market size is expected to see rapid growth in the next few years. It will grow to $3.61 billion in 2030 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to increasing adoption of precision medicine approaches, rising pharmaceutical r&d spending, expansion of organoid applications in regenerative medicine, technological advances in 3D cell culture systems, growing demand for human-relevant disease models. Major trends in the forecast period include growing adoption of organoids in drug discovery and toxicity testing, increasing use of organoids for disease modeling and pathophysiology studies, rising demand for personalized medicine using patient-derived organoids, expansion of organoid applications in oncology and neurology research, increasing collaboration between academia and pharma for organoid-based research.

The increasing number of experiments in genetic science is expected to drive growth in the human organoids market. Genetic science, the branch of biology that studies inheritance and the influence of genes on the development and function of living organisms, is seeing a rise in experiments due to technological breakthroughs that make gene editing faster and more precise. These advancements enable deeper research into diseases and the development of targeted treatments. Human organoids benefit from genetic science by allowing precise gene manipulation to model specific diseases and study their progression. This facilitates better understanding of genetic disorders, drug testing, and exploration of personalized treatment strategies. For instance, in April 2024, the American Society of Gene & Cell Therapy reported that in Q4 2023, the number of phase III gene therapy clinical trials increased by 10%, marking the first quarterly rise since Q3 2022. Therefore, the rising number of experiments in genetic science is driving the human organoids market.

Key companies in the human organoids market are focusing on developing advanced culture platforms and materials to enhance cell viability and oxygen delivery, improving the accuracy and scalability of in vitro models for drug discovery, regenerative medicine, and personalized therapy. For example, in June 2025, Mitsui Chemicals Group, a Japan-based chemical manufacturer, introduced InnoCell oxygen-permeable cell culture microplates. These microplates enhance oxygen delivery to cells, particularly in 3D spheroid and organoid cultures, reducing cell death and improving long-term viability. They are available in both non-treated (N-type) and collagen-coated (C-type) versions to accommodate diverse cell types and feature low drug adsorption and excellent fluorescence imaging properties. These advancements support drug discovery, personalized medicine, regenerative therapies, and advanced in vitro modeling in pharmaceutical research.

In January 2025, Merck Group, a Germany-based pharmaceutical company, acquired HUB Organoids Holding B.V. for an undisclosed amount. This acquisition strengthens Merck’s next-generation biology portfolio by integrating advanced organoid technology to accelerate drug development, improve treatment insights across populations, and reduce animal testing, reinforcing its commitment to innovative and ethical life sciences solutions. HUB Organoids Holding B.V., based in the Netherlands, specializes in human organoid research and applications.

Major companies operating in the human organoids market are Organovo Holdings Inc., Emulate Inc., MIMETAS B.V., InSphero AG, DefiniGEN Limited, CN Bio Innovations Limited, CELLINK AB, Hubrecht Organoid Technology, Stemcell Technologies Inc., Crown Bioscience Inc., Synthego Corporation, Altis Biosystems Inc., Molecular Devices LLC, TissUse GmbH, Nortis Inc., Hesperos Inc., Vivodyne Inc., Curi Bio Inc., Axol Bioscience Ltd.

North America was the largest region in the human organoids market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human organoids market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human organoids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the human organoids market by increasing the cost of imported cell culture reagents, stem cell lines, bioprinting equipment, and advanced laboratory instruments used in organoid development. These impacts are most evident in research-intensive segments and in regions such as North America and Europe that depend on global life sciences supply chains. Higher input costs may slow adoption in smaller research settings; however, tariffs are also encouraging domestic manufacturing of reagents, local sourcing of lab consumables, and innovation in cost-efficient organoid production technologies, supporting long-term market sustainability.

The human organoids market research report is one of a series of new reports that provides human organoids market statistics, including human organoids industry global market size, regional shares, competitors with a human organoids market share, detailed human organoids market segments, market trends and opportunities, and any further data you may need to thrive in the human organoids industry. This human organoids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Human organoids are three-dimensional, miniature, lab-grown representations of human organs derived from stem cells. They replicate the structure and function of real organs on a small scale and are used in research to study human development, disease mechanisms, and drug responses in a controlled environment.

The main types of human organoids include brain organoids, heart organoids, intestinal organoids, kidney organoids, liver organoids, lung organoids, and pancreatic organoids. Brain organoids are miniature, lab-grown models of the human brain developed from stem cells. These organoids are created using advanced technologies such as 3D bioprinting, cell culture techniques, hydrogels and scaffold-based approaches, and magnetic levitation. They are applied in drug discovery, infectious disease research, neurology studies, oncology research, personalized medicine, and regenerative medicine. The primary end users of human organoids include pharmaceutical and biotechnology companies, contract research organizations, and academic and research institutions.

The human organoids market include revenues earned by entities by providing services such as drug discovery and development, disease modeling, toxicology testing, regenerative medicine research, and biomarker discovery. The market value includes the value of related goods sold by the service provider or included within the service offering. The human organoids market also consists of sales of products including organoid-based therapeutics, disease modeling solutions, drug testing platforms, and research applications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.